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The variability within an in vivo animal model depends on 
multiple factors, including pathogen status. Many bacterial and 
viral agents that can infect mice have been shown to be intercur-
rent variables in murine models of human disease. Inapparent 
infections may cause undesirable variability, unexplainable data 
variation, or misinterpretation of data.1,18 Since the discovery and 
recognition of murine norovirus (MNV) as prevalent in mouse 
colonies9,11 and the identification of numerous strains of MNV that 
are biologically and genetically distinct,11,14,24 questions have been 
raised about how infection with this virus might affect mouse 
models of human disease.
MNV1 initially was reported in Stat1−/− mice.13 Although Stat1−/− 
mice, which have abnormal signaling through interferon path-
ways, develop lethal disease when infected with MNV, MNV 
does not appear to cause clinical disease in wildtype mice or in 
several other strains of immunodeficient mice, such as recom-
bination-activating gene-deficient (Rag−/−) or inducible nitric ox-
ide synthase-deficient mice.13,29 Like human noroviruses, which 
cause inflammatory changes in the gastrointestinal tract,16 MNV 
appears to be transmitted easily by the orofecal route13 and has 
been associated with histologic changes in the intestine of immu-
nocompetent mice.25 MNV has a tropism for dendritic cells and 
macrophages,30 which are important players in immunologic and 
inflammatory responses. Studies in Rag−/− mice demonstrate that 
adaptive immune responses play an important role in clearance 
of virus and that CD4+ and CD8+ T cells and B cells are impor-
tant in this process as well.13,31 Only a few studies have exam-
ined the potential effects of MNV infection on mouse models. 
A recent study6 found that MNV has the subtle but definite ef-
fect of depressing CD8+ T cell responses in a model of murine 
cytomegalovirus infection. In contrast, another study10 found that 
MNV infection had no significant effect on adaptive immune re-
sponses to vaccinia virus or influenza A virus. Our laboratory 
demonstrated that MNV4 infection accelerated the progression 
of Helicobacter-induced inflammatory bowel disease (IBD) in the 
FVB.129P2-ABC1atm1BorN7 (Mdr1a−/−) mouse and that this induc-
tion was mediated in part through alteration of dendritic and 
T-cell cytokine responses.17
Our laboratory studies bacteria-induced IBD3 and inflamma-
tion-associated colon cancer20,22 by using SMAD3-deficient mice. 
Smad3−/− mice are deficient in TGFβ signaling due to the absence 
of SMAD3, a molecule involved in signal transduction from the 
membrane-bound TGFβ receptor to the nucleus. TGFβ dysregula-
tion results in the development of transient bacteria-induced coli-
tis when mice are infected with Helicobacter; this transient colitis 
then progresses to colon cancer.22 The model has a strong inflam-
matory component and is characterized by dysregulation of both 
adaptive22 and innate21 immune responses.
Because MNV can reside in both macrophages and dendritic 
cells, which are pivotal in inflammatory responses, we reasoned 
that this model could potentially be altered by concurrent MNV 
infection. In contrast to the previous report on Mdr1a−/− mice,17 we 
report here that MNV4 infection does not affect the progression or 
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Serology and fecal PCR. Serum was separated from cardiac 
blood collected at necropsy, frozen, and stored at −80 °C until 
processing. Seroconversion to MNV was confirmed in studies 1 
and 2. Antibodies to MNV were detected by microsphere-based 
serologic multiplexed fluorescent immunoassay with second-
ary testing by indirect fluorescent antibody analysis (Research 
Animal Diagnostic Laboratory, Columbia, MO, or Department of 
Comparative Medicine, University of Washington, Seattle, WA).
For confirmation of MNV in feces, RT–PCR analysis was done 
on RNA extracted from feces4 collected from animals in studies 
1 (8 wk after infection), 2 (1 wk after infection), and 3 (2 to 3wk 
after infection). RT–PCR for MNV was performed as previously 
described with slight modification.12 Briefly, the RNA was ampli-
fied by using a commercial kit (OneStep RT-PCR Kit, Qiagen, Va-
lencia, CA). The RT-PCR mixture was heated at 50 °C for 30 min 
and at 95 °C for 15 min, followed by 40 cycles consisting of 94 °C 
for 1 min, 59 °C for 30 s, and 72 °C for1 min, with a final primer 
extension at 72 °C for 10 min.
For confirmation of H. bilis infection in studies 1 through 3, fe-
cal samples were collected at least 7 d after infection. DNA was 
extracted by using a commercial kit (QIAamp DNA mini-kit, Qia-
gen). Helicobacter spp. PCR was performed as described.3
Pathology. Necropsy, tissue sampling, processing, and histolog-
ic examination (with some modifications) were done as described 
previously.3 Cecum, colon, and rectum were fixed in 10% buffered 
formalin. The colon was prepared in a ‘Swiss roll’ technique to 
evaluate the entirety of the proximal, middle, and distal colon 
on the same section. Tissues were processed routinely in neutral-
buffered formalin, embedded in paraffin, sectioned at 4 to 5 μm, 
and stained with hematoxylin and eosin. Tissues were scored for 
inflammation and dysplasia by a pathologist, and each mouse 
was scored for severity of mucosal epithelial changes, degree of 
inflammation, and extent of pathology. The total inflammation 
and dysplasia score for each mouse (IBD score)21 was derived 
by summing the scores from the individual segments and, sub-
sequently, the mean was calculated for each treatment group. 
Tumors were counted and classified as invasive (mucinous ad-
enocarcinomas penetrating the tunica muscularis) or noninva-
sive (adenomas with high-grade dysplasia and intraepithelial 
carcinomas).2,22
In vitro infection of bone marrow-derived macrophages and 
cytokine analyses. Bone marrow was isolated from Smad3−/− and 
Smad3+/+ (wildtype) mice. RBC were lysed by incubating cells in 
Gey solution (ammonium chloride RBC lysis buffer) for 5 min at 
room temperature. After RBC lysis, remaining cells were differen-
tiated to macrophages by culture for 10 to 12 d in the presence of 
conditioned medium from L929 cells expressing macrophage col-
ony-stimulating factor.7 Aliquots of 1 × 106 macrophages were cul-
tured overnight in RPMI containing 5% FCS and gentamycin at 
37 °C. MNV was added at a multiplicity of infection of 2.5 and in-
cubated for 6 h. H. bilis sonicate with a total protein concentration 
of 16 mg/mL (determined by absorbance at 280 nm) was added 
to cultures at a final concentration of 0.2 ng/mL (low Hb) and 4 
ng/mL (high Hb), and cultures were incubated for another 24 h. 
RNA was extracted (RNeasy Mini Kit, Qiagen, and Qiashredder 
columns, Qiagen), converted into cDNA (SuperScript SSIII kit, 
Invitrogen, Carlsbad, CA) by using oligodT primers, and assayed 
for TNFα, IL6, and IL1β expression by using real-time PCR (Pow-
erSybrGreen PCR master mix; Life Technologies–ABI, Carlsbad, 
CA) on a Mx3005P apparatus (Stratagene, La Jolla, CA). Cytokine 
phenotype of tumors in Helicobacter-infected Smad3−/− mice. How-
ever, in vitro studies using bone-marrow–derived macrophages 
(BMDM) from Smad3−/− and wildtype mice did show differences 
in cytokine profiles after infection with MNV4 and H. bilis.
Materials and Methods
Animals, infections, and experimental design. 129-Smad3tm/Par/J 
(Smad3−/−) mice initially were obtained from The Jackson Labo-
ratory (Bar Harbor, ME). Animals were housed at the Univer-
sity of Washington in a specific pathogen-free facility in static 
micro-isolator (Alternative Design, Siloam Springs, AR) or indi-
vidually ventilated cages (Allentown, Allentown, NJ) containing 
corncob bedding (Andersons, Maumee, OH) and cotton nesting 
pads. Mice were fed irradiated rodent chow (Animal Specialties, 
Portland, OR) and autoclaved, acidified water. All supplies enter-
ing animal rooms were autoclaved or gas-sterilized, and rooms 
were maintained at 20 to 23 °C, with a 12:12-h light:dark cycle. To 
prevent cross-contamination of Helicobacter-uninfected and -in-
fected mice, cages were changed in dedicated changing stations. 
Sentinel mice (Crl:CD1[ICR]; Charles River, Wilmington, MA) 
were tested quarterly for endo- and ectoparasites, MNV, mouse 
hepatitis virus, mouse parvovirus, and rotavirus and annually for 
Mycoplasma pulmonis, pneumonia virus of mice, reovirus 3, Sendai 
virus, and Theiler murine encephalomyelitis virus. In addition, 
yearly fecal colon samples were screened for Citrobacter rodentium, 
nonlactose-fermenting Escherichia coli, Salmonella spp., Klebsiella 
spp., and Clostridium spp. (Phoenix Laboratories, Everett, WA). 
During the study period, all sentinels were negative for the listed 
pathogens, except for sentinels on the infected racks, which sero-
converted to MNV and were PCR-positive for Helicobacter spp. 
All animal procedures were approved by the University of Wash-
ington Institutional Animal Care and Use Committee.
Age-matched Smad3−/− mice (male and female, 2 to 5 mo old) 
were used in 4 different infection studies. Study treatment groups, 
animal numbers and duration are outlined in Figure 1. MNV4 (a 
kind gift from L Riley, University of Missouri, Columbia, MO) 
stocks were propagated in RAW264.7 cells, a transformed murine 
macrophage cell line. RAW264.7 cells were PCR-negative for mu-
rine leukemia virus.8 Subconfluent cultured cells were infected 
with MNV at a multiplicity of infection of 0.05 and incubated 
for 48 to 72 h, as described.12 MNV was recovered by successive 
freeze–thaw cycles, concentrated by centrifugation at 90,000 × g 
for 3 h, and titered by plaque assay with RAW264.7 cells.
Mice were inoculated with either 1 × 106 or 5 × 106 plaque-form-
ing-units MNV4 in 0.2-mL RAW264.7 (RAW) cell lysate clarified 
by centrifugation at 3000 x g for 10 min or sham-inoculated with 
0.2 mL DMEM or RAW cell lysate on day 0. H. bilis was a natural 
isolate kindly provided by L Riley (University of Missouri). Or-
ganisms were prepared for infection as previously described,17 
and mice were inoculated 1 wk after MNV infection with 0.2 mL 
H. bilis in Brucella broth for a dose of 2 × 107 or 1 × 105 cfu per 
mouse. Note that in study 1, H. bilis was given in 2 doses, on day 
7 and 8 after infection with MNV or sham-inoculation.
Mice were euthanized by CO2 when they developed severe 
diarrhea, 20% body weight loss, significant anemia, or signs of ill-
ness during the study (Figure 1); remaining mice were euthanized 
at the end of the study. At necropsy, blood samples were obtained 
through cardiac puncture, and tissue samples for histopathology 
were taken from the cecum and colon.
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were excluded from tumor and IBD analysis due to uncertainty of 
whether tumors would have developed with more time. Animals 
that died of complications not related to IBD or cancer also were 
excluded from the analysis. A value of P ≤ 0.05 was considered 
significant for all tests.
Results
Cytokine profiles of macrophages from wildtype and Smad3−/− 
mice infected with MNV4 in vitro. Because MNV can persistently 
infect macrophage cell lines,5 we cultured BMDM from Smad3−/− 
and Smad3+/+ (wildtype) mice with MNV4 at a multiplicity of in-
fection of 2.5. Because our in vivo IBD-induced cancer model in 
Smad3−/− mice involves infection with H. bilis, we tried to mimic 
double infection in vitro; therefore some treatment groups also 
were cultured in the presence of H. bilis sonicates. After 30 h of 
incubation, RNA was extracted and cytokine expression was de-
termined by quantitative real-time PCR. Incubation of BMDM 
with MNV alone caused increases in expression of the inflamma-
tory cytokines TNFα, IL6, and IL1β (Figure 2 A), ranging from a 
1.8- (wildtype TNFα) to 28- (Smad3−/− IL1β) fold increase in cy-
tokine gene expression compared with untreated controls. In ad-
dition, MNV enhanced the cytokine expression of cells treated 
with H. bilis sonicates (Figure 2 B), and the magnitude of the ef-
fect differed with a high or low concentration of H. bilis. In both 
wildtype and Smad3−/− macrophages, the largest increases with 
levels in treated macrophages are expressed relative to those of 
the control (uninfected macrophages of the same genotype). Rela-
tive expression of cytokine genes compared with control samples 
was calculated by using MxPro software (Agilent, Santa Clara, 
CA). Primer sequences were: TNFα forward, 5′AGC CGA TGG 
GTT GTA CCT TGT CTA; TNFα reverse, 5′ TGA GAT AGC AAA 
TCG GCT GAC GGT; IL1β forward, 5′ CTT CAG GCA GGC AGT 
ATC ACT CAT; IL1β reverse, 5′ AAG AAG GTG CTC ATG TCC 
TCA TCC; IL6 forward, 5′ ATC CAG TTG CCT TCT TGG GAC 
TGA; IL6 reverse, 5′ TAA GCC TCC GAC TTG TGA AGT GGT.
Statistics. For tissue culture experiments (Figure 2), the Student 
t test was used to show significant differences compared with 
control samples. One-way ANOVA followed by the Tukey mul-
tiple comparison test was used to determine significant increases 
in H. bilis-treated tissue culture samples compared with H. bilis- 
and MNV-cotreated samples. Kaplan–Meier survival curves were 
generated, and significance determined with the log-rank (Man-
tel–Cox) test statistic by using GraphPad Prism 5 (GraphPad Soft-
ware, La Jolla, CA). Animals that died due to reasons unrelated 
to IBD or cancer or that lived to the endpoint of the study were 
censored in the analysis. Differences between group IBD scores 
and tumor scores were analyzed with Kruskall–Wallis ANOVA 
with Dunn posttest (studies 3 and 4) or by the Mann–Whitney test 
(studies 1 and 2). Fisher exact contingency statistics were used 
to compare tumor incidence between groups. Animals that died 
before 10 wk after infection with H. bilis that did not have tumors 
Figure 1. Design of studies.
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an additional experimental group received RAW264.7 cell lysate 
only. Neither RAW cell lysate nor MNV4 infection alone affected 
survival in this model (Figure 3 C and D).
Effects of MNV4 infection on the severity of endpoint IBD, tu-
mor burden, and tumor phenotype in Smad3−/− mice. Smad3−/− 
mice develop IBD after infection with Helicobacter, characterized 
by colonic epithelial cell hyperplasia and inflammation which 
may persist until late in the disease process.22 Because we previ-
ously found that the severity of Helicobacter-induced IBD was 
affected by MNV4 infection in Mdr1a−/− mice,17 we compared the 
IBD scores between MNV4-infected and -uninfected Smad3−/− 
mice. Histologic scoring of the cecum and colon found no sta-
tistically significant differences between coinfected (MNV and 
H. bilis) and singly infected (H. bilis only) groups in any of the 4 
studies (Figure 4, Table 1). IBD scores in study 4 were somewhat 
lower than those in other studies, possibly due to the shortened 
duration of this particular study; nonetheless IBD scores did not 
differ significantly between the 2 groups. Because Smad3−/− mice 
can develop a variety of tumors throughout the colon and rectum, 
our histopathologic analysis differentiated between invasive and 
noninvasive neoplasia. In all studies, the overall average tumor 
burden (number of distinct invasive or noninvasive tumors per 
mouse) was not statistically different. In addition, the number 
MNV infection were in levels of IL1β at the low dose of H. bilis 
compared with H. bilis alone (21-fold increase in wildtype and 12-
fold increase in Smad3−/−) and IL6 (7-fold increase in wildtype and 
6.4-fold increase in Smad3−/−). Because macrophage-derived in-
flammatory cytokines are important in the Smad3−/− mouse model 
of IBD-associated colon cancer, these data suggested that concur-
rent MNV infection might alter the phenotype. We, therefore, 
evaluated whether concurrent MNV infection altered the in vivo 
model in Smad3−/− mice.
Survival of Smad3−/− mice infected with Helicobacter and MNV4. 
Four independent studies were performed to examine the ef-
fect of MNV infection on IBD and colon cancer development in 
Helicobacter-infected Smad3−/− mice. As an overall measure of the 
progression of disease, we examined the effect of MNV4 infection 
on survival until the experimental endpoint. In study 1, Smad3−/− 
mice first were inoculated with MNV or broth on day 0 followed 
by H. bilis infection on days 7 and 8, and mice were euthanized 
and necropsied at 32 wk after infection. Median survival did not 
differ between groups (median survival: coinfected mice, 157.0 
d; singly infected mice, 148.5 d; P = 0.1643; Figure 3 A). In stud-
ies 2, 3, and 4, Smad3−/− mice were infected with MNV4 and then 
infected with H. bilis on day 7 only. Again, median survival was 
not different between groups (Figure 3 B through D). In study 4, 
Figure 2. Inflammatory cytokine expression in BMDM is altered with MNV infection in vitro. (A) Relative expression of the indicated cytokine genes 
in BMDM incubated with MNV compared with control cultures. (B) Relative gene expression of indicated cytokines in BMDM incubated with H. bilis 
sonicate (Hb) alone or with MNV and 1 of 2 doses (low, 0.2 ng/mL; high, 4 ng/mL) of Hb. Cytokine expression was determined by quantitative RT–
PCR. Cytokine levels in treated macrophages are expressed relative to those of controls (uninfected macrophages). Error bars indicate 1 SEM (n = 4) in 
a single experiment; data for 1 of 2 independent experiments are shown. *, Value significantly (P < 0.05, unpaired t test) different from that of control; 
+, value significantly (P < 0.05, ANOVA with Tukey post test) different from value after Hb treatment alone.
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to 64%. Whereas the first isolate, MNV1, caused fatal disease in 
immunocompromised mice, such as Stat1−/− and interferon-sig-
naling–deficient (IFNαβγR−/−) mice,13 MNV does not cause any 
overt disease in immunocompetent mice. However, we found 
that MNV induces subtle changes in lymphoid tissue of immu-
nocompetent wildtype mice26 and that MNV infection can exac-
erbate IBD in a commonly used mouse model, Mdr1a−/− mice.17 
Effects of MNV on IBD in the Mdr1a−/− model were due in part to 
changes in antigen-presenting cells, such as dendritic cells and 
macrophages, for which MNV has a demonstrated tropism.30 
Because macrophages are important players in inflammatory 
responses (particularly inflammation-associated cancer)28 and 
because heightened macrophage responses and enhanced cyto-
kine elaboration play a role in bacteria-induced inflammation 
in the Smad3−/−22 and Smad3 −/− Rag2 −/− models21 of colon cancer, 
we wondered whether MNV infection would alter the pheno-
type of the Smad3−/− model. Because MNV can cause persistent 
infection and subtle, subclinical immunologic changes—even in 
immunocompetent mice—and replicates in both epithelium and 
antigen-presenting cells in the gut, there is considerable concern 
that this virus could alter mouse models of disease, especially 
those involving intestinal inflammation.
In vitro experiments in both wildtype and Smad3−/− BMDM 
indicated that MNV alone could alter inflammatory cytokine 
of mice developing either noninvasive or invasive tumors was 
not significantly different between groups (Figure 4, Table 1). No 
tumors developed in Smad3−/− mice given broth or MNV alone; 
however, 1 of 9 mice given RAW cell lysate in study 4 developed 
an invasive adenocarcinoma, an unusual occurrence in this model.
Infection status of MNV4-inoculated Smad3−/− mice. Fecal sam-
ples were collected at 2 time points in 2 different studies, and the 
presence of MNV4 was demonstrated by using fecal RT-PCR. In 
study 1, all 11 MNV4-infected mice were positive for MNV4 in 
feces at 8 wk after infection, and all 10 mice infected with H. bilis 
only remained negative for MNV4 in feces. MNV4 was detected 
in feces as early as 1 wk after infection. In study 3, 11 of 12 MNV4-
infected mice were positive for MNV4 in feces, whereas none of 
the control or mice infected with H. bilis alone was positive for 
MNV4. Endpoint serology was used in studies 1 and 2 to deter-
mine seroconversion to MNV4. The combined results from stud-
ies 1 and 2 showed that all 16 mice that were infected with H. bilis 
only were seronegative for MNV at 1 to 32 wk after infection, and 
all 21 mice infected with MNV seroconverted to MNV as early as 
1 to 32 wk after infection.
Discussion
MNV is endemic in many animal facilities in the United States, 
Canada,9,27 Europe,24 and Asia,15,32 with prevalence as high as 58% 
Figure 3. Survival of Smad3−/− mice coinfected with MNV and H. bilis (MNV+Hb) or infected with H. bilis only (Hb). Survival curves from studies 1 to 
4 are shown (A through D, respectively). There was no significant difference in survival between coinfected and singly infected animals in any of the 4 
studies. In C and D, survival of either infected group was significantly (P ≤ 0.05) different from that of control animals (broth, MNV, or lysate).
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vival, tumor burden, or phenotype between Smad3−/− mice coin-
fected with MNV and H. bilis or with H. bilis alone.
Our studies were limited with regard to several aspects of in-
fection (infectious dose, virus isolate, and timing of infection) that 
could affect the degree of the response of the Smad3−/− mouse 
model to a concurrent MNV infection. We tested 2 infectious dos-
es of MNV (1 × 106 and 5 × 106 pfu) and used a single naturally oc-
curring isolate of MNV, MNV4.11 The MNV infection was initiated 
prior to the main trigger of disease in our model (infection with 
H. bilis) but not during or late in the disease process. We cannot 
exclude the possibility that a different dose, strain, or timing of 
infection would have altered the phenotype of the model. In addi-
tion, multiple strains of MNV are likely present in mouse colonies 
in the United States, and the biology of MNV can vary substan-
tially with each virus isolate.14 Previous infection with MNV does 
not necessarily confer protection from subsequent infections even 
with the same strain, as shown in C56BL/6 and 129Sv/Ev mice.19 
In an infected colony, some mice likely would become infected or 
reinfected at different time points during an experimental course, 
especially if they are being brought in from a MNV-free commer-
cial vendor into an endemically infected colony.
Studies of the pathophysiologic effects and immunologic re-
sponses of this ubiquitous virus are still in their infancy. Although 
we did not observe an effect of MNV infection on the Smad3−/− 
mouse model, these results cannot necessarily be extrapolated 
production by macrophages. Increased cytokine production has 
recently been demonstrated in MNV1-infected bone-marrow–
derived dendritic cells of wildtype animals and was shown to be 
dependent on viral interaction with pattern recognition receptors 
Mda5 and possibly TLR3.23 Our data demonstrate that infection 
of BMDM with MNV4 can enhance production of cytokines in 
response to bacterial (H. bilis) antigens. BMDM treated with a 
low dose of H. bilis extract responded weakly in their produc-
tion of IL6 and IL1β RNA. However, infection of BMDM with 
MNV4 prior to treatment with low-dose H. bilis extract increased 
cytokine production 8.6- (IL6) and 21- (IL1β) fold.
Despite the results from our in vitro experiments, MNV4 infec-
tion prior to infection with H. bilis in vivo did not significantly 
alter endpoint IBD and subsequent cancer in Smad3−/− mice. 
Although IBD scores were not increased at the 17- to 32-wk 
endpoints in the coinfected Smad3−/− mice, IBD in this model is 
primarily tumor-associated, and inflammation is being driven 
by tumor development instead of or in addition to the ongoing 
Helicobacter infection. Perhaps MNV4 infection was associated 
with increased inflammation earlier in the disease process that 
was being driven by Helicobacter, similar to what we observed in 
the MDR1a−/− model.17 However, if this increase did occur, it was 
not robust enough to cause significant changes in the endpoint 
experimental outcomes in this model, as reflected in overall sur-
Figure 4. IBD and neoplasia in Smad3−/− mice infected with H. bilis alone or coinfected with MNV and H. bilis. IBD scores (left), number of invasive le-
sions (middle), and number of noninvasive lesions (right) are shown for (A) study 2 and (B) study 3. In study 3, 2 additional control groups of mice were 
infected with MNV alone (n = 6) or broth only (n = 4) are shown. Black bars above graphs in (B) indicate statistically significant differences between 
groups as tested by nonparametric one-way ANOVA and a Dunn post test. There were no statistically significant differences between mice coinfected 
with both MNV and H. bilis or with H. bilis only (P > 0.05 for Mann–Whitney tests of IBD and tumor scores; P > 0.05 for Fisher exact test for tumor 
incidence).
Murine norovirus does not affect mouse colon cancer
225
 5. Daughenbaugh KF, Wobus CE, Hardy ME. 2006. VPg of murine 
norovirus binds translation initiation factors in infected cells. Virol 
J 3:33. 
 6. Doom CM, Turula HM, Hill AB. 2009. Investigation of the impact of 
the common animal facility contaminant murine norovirus on experi-
mental murine cytomegalovirus infection. Virology 392:153–161. 
 7. Englen MD, Valdez YE, Lehnert NM, Lehnert BE. 1995. Granulo-
cyte–macrophage colony-stimulating factor is expressed and secreted 
in cultures of murine L929 cells. J Immunol Methods 184:281–283. 
 8. Hartley JW, Evans LH, Green KY, Naghashfar Z, Macias AR, Zer‑
fas PM, Ward JM. 2008. Expression of infectious murine leukemia 
viruses by RAW264.7 cells, a potential complication for studies with 
a widely used mouse macrophage cell line. Retrovirology 5:1. 
 9. Henderson KS. 2008. Murine norovirus, a recently discovered and 
highly prevalent viral agent of mice. Lab Anim (NY) 37:314–320. 
 10. Hensley SE, Pinto AK, Hickman HD, Kastenmayer RJ, Bennink JR, 
Virgin HW, Yewdell JW. 2009. Murine norovirus infection has no 
significant effect on adaptive immunity to vaccinia virus or influenza 
A virus. J Virol 83:7357–7360. 
 11. Hsu CC, Riley LK, Wills HM, Livingston RS. 2006. Persistent 
infection with and serologic cross-reactivity of 3 novel murine no-
roviruses. Comp Med 56:247–251.
 12. Hsu CC, Wobus CE, Steffen EK, Riley LK, Livingston RS. 2005. 
Development of a microsphere-based serologic multiplexed fluores-
cent immunoassay and a reverse-transcriptase–PCR assay to detect 
murine norovirus 1 infection in mice. Clin Diagn Lab Immunol 
12:1145–1151.
 13. Karst SM, Wobus CE, Lay M, Davidson J, Virgin HW 4th. 2003. 
STAT1-dependent innate immunity to a Norwalk-like virus. Science 
299: 1575–1578.
 14. Kelmenson JA, Pomerleau DP, Griffey S, Zhang W, Karolak MJ, 
Fahey JR. 2009. Kinetics of transmission, infectivity, and genome 
to other mouse models of IBD or cancer progression. As we are 
gradually acquiring more information on the biology and effect 
of MNV infection in specific mouse models, researchers should 
be cautious when dealing with MNV-positive mouse colonies 
and consider intercurrent viral infection as a potential cause of 
experimental variability. Studies that find no apparent effect of 
MNV infection on the model being studied are as important to 
report as those that detect positive effects.
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